Respiratory News and Research

RSS

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Researchers at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center found that monoclonal antibodies, a COVID-19 treatment administered early after infection, reduce the risk of hospitalization and death by 60 percent in people at high risk of suffering complications from the condition.

20 May 2021

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Researchers in the UK have demonstrated the efficacy of the Pfizer-BioNTech and AstraZeneca vaccines against severe acute respiratory virus coronavirus 2 (SARS-CoV-2) at preventing death among older individuals with coronavirus disease 2019 (COVID-19).

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

The effects of SARS-CoV-2 vaccination on pregnancy and birth

The severe impact of this infection has given rise to a study by Theiler et al. (2021), which investigated the effects of SARS-CoV-2 vaccination in pregnancy in order to examine the protection it could provide to combat the infection.

19 May 2021

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.

19 May 2021

Working conditions and non-workplace factors affect COVID-19 mortality in England

Researchers from England recently estimated occupational variations in COVID-19 mortality in England and Wales during 2020 and examined how these differences changed post adjustment for non-workplace factors.

19 May 2021

B.1.1.7 not associated with change in serial interval of COVID-19

With data obtained from the Virus Watch study in England and Wales, researchers found that the serial interval of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is broadly similar to estimates from previous studies and there is no evidence that the B.1.1.7 variant is associated with any change.

19 May 2021

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Scientists have recently investigated the dynamics of immune responses in elderly people who have received two doses of the Pfizer/BioNTech COVID-19 vaccine.

19 May 2021

Virtual analysis identifies a potential natural inhibitor of SARS-CoV-2 Nsp15

A new paper reports the discovery of promising antiviral hit compounds through the use of computational modeling studies on natural compounds.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Researchers have reported the first case of COVID-19 triggering a rare occurrence of potentially severe blood clots forming in the arms.

19 May 2021

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

Once dismissed as a conspiracy theory, the idea that the covid virus escaped from a Chinese lab is gaining high-profile attention. As it does, reputations of renowned scientists are at risk — and so is their personal safety.

19 May 2021

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

Researchers at St Jude Children’s Research Hospital found that toll-like receptor 2 detects the SARS-CoV-2 envelope protein-producing inflammatory cytokines.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

New research published on the preprint server bioRxiv* performed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic simulations to understand the evolutionary transition from a bat-adapted SARS-CoV-2 to a human-adapted virus.

19 May 2021

Respiratory News and Research

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

The effects of SARS-CoV-2 vaccination on pregnancy and birth

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Working conditions and non-workplace factors affect COVID-19 mortality in England

B.1.1.7 not associated with change in serial interval of COVID-19

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Virtual analysis identifies a potential natural inhibitor of SARS-CoV-2 Nsp15

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News